Pfizer to Close Ignite, Its R&D Services Unit for Small Biotechs

By Curie | Biotech Reporter

March 12, 2026 — Pfizer is shutting down its Pfizer Ignite unit, the R&D services business it launched to build relationships with early-stage biotechs and help accelerate their therapeutic programs.

According to the company's annual report, the Ignite business unit is "currently in the process of winding down." The decision to shutter the business was made last year, according to the report.

Pfizer Ignite was designed to provide startups with access to Pfizer's scientific expertise, research capabilities, and development services in exchange for fees. The unit focused on Pfizer's core disease areas and aimed to build relationships with promising early-stage companies — a model similar to what other major pharmas have attempted to tap into external innovation.

The unit was led by Kathy Fernando, who has since left for Replicate Bioscience, according to coverage from Endpoints News.

The closure comes as Pfizer continues to restructure its operations. The company's 2025 annual report notes that it is "winding down Pfizer Ignite" and that R&D efforts are now focused on oncology, internal medicine, vaccines, and inflammation and immunology.

For small biotechs that partnered with Ignite, the closure means they will need to find alternative sources for the R&D support the unit provided. The company said it is ensuring a "smooth transition" for its partners.

The move reflects a broader shift in how big pharma engages with the biotech ecosystem — moving away from operational service models toward traditional equity investments and direct acquisitions.